RESEARCH ARTICLE
In Vitro Elution Characteristics of Gentamicin and Vancomycin from Synthetic Bone Graft Substitutes
Gerrit Steffen Maier*, 1, Klaus Edgar Roth1, Stefan Andereya2, Klaus Birnbaum3, Christopher Niedhart4, Markus Lühmann5, Jörg Ohnsorge5, Uwe Maus6
Article Information
Identifiers and Pagination:
Year: 2013Volume: 7
First Page: 624
Last Page: 629
Publisher ID: TOORTHJ-7-624
DOI: 10.2174/1874325001307010624
Article History:
Received Date: 24/7/2013Revision Received Date: 15/10/2013
Acceptance Date: 21/10/2013
Electronic publication date: 3 /11/2013
Collection year: 2013

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Objects:
Beta tricalciumphosphate pellets loaded with individualized antibiotics may represent novel options in the treatment of osteomyelitis and infectious bone disease. Here, the in vitro antibiotic elution of vancomycin and gentamicin from the synthetic bone graft substitutes Cerasorb® and Cerasorb M® was tested.
Methods:
Antibiotic elution and concentration of gentamcin and vancomycin were measured using photometrically-based measurement and homogeneous particle-enhanced turbidimetric inhibition immunoassays (PETINIA).
Results:
Initially both materials showed a high release of the loaded antibiotics, with Cerasorb M® showing lower release levels for gentamicin and vancomycin than Cerasorb®. Gentamicin concentrations of Cerasorb M granules and Cerasorb were below the minimum detectiontreshold until day four and six of the experiment respectively. The vancomycin release-level followed a similar pattern, although the vancomycin concentration eluted by Cerasorb M® granules stayed above the detection threshold during the experimental time.
Conclusions:
Cerasorb® and Cersorb M® may represent a new treatment option in osteomyelitis and infectious bone disease.